drugset / Trial / NCT02988024

Pilot BA Study of New LY03005 vs Pristiq

NCT02988024

Phase 1 Completed 20 enrolled Luye Pharma Group Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The objects of this study is to assess the relative bioavailability (BA) of 80 mg LY03005 oral tablets compared to 50 mg Pristiq® oral tablets after a single oral intake under fasting conditions in healthy subjects between 18 and 50 years of age.

Timeline

Start
2016-12-07
Primary completion
2016-12-28
Completion
2016-12-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Desvenlafaxine Other / unclassified 50 mg Oral
Subject Toludesvenlafaxine Small molecule 80 mg Oral